The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-08-18
DOI
10.1038/s41598-017-09548-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Review article: sarcopenia in cirrhosis - aetiology, implications and potential therapeutic interventions
- (2016) M. Sinclair et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice
- (2016) Yanbo Fan et al. GASTROENTEROLOGY
- Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study
- (2016) Jeffrey Cui et al. HEPATOLOGY
- Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes
- (2016) Mohammed Eslam et al. HEPATOLOGY
- Inactivation ofTm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins
- (2016) Eriks Smagris et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease
- (2016) Salvatore Petta et al. JOURNAL OF HEPATOLOGY
- MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C
- (2016) Khaled Thabet et al. Nature Communications
- Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes
- (2016) Silvia Sookoian et al. Scientific Reports
- The dual and opposite role of theTM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis
- (2015) Carlos J. Pirola et al. HEPATOLOGY
- Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients
- (2015) Marta Milano et al. HEPATOLOGY
- Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease
- (2015) Paola Dongiovanni et al. HEPATOLOGY
- Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity
- (2015) Silvia Sookoian et al. HEPATOLOGY
- TM6SF2rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C
- (2015) Salvatore Petta et al. LIVER INTERNATIONAL
- TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism
- (2015) Nicola Coppola et al. LIVER INTERNATIONAL
- A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis
- (2015) Stephan Buch et al. NATURE GENETICS
- Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis
- (2015) Paola Dongiovanni et al. Biomed Research International
- The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis
- (2014) Amit G Singal et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases
- (2014) Francesco Negro JOURNAL OF HEPATOLOGY
- Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk
- (2014) Oddgeir L Holmen et al. NATURE GENETICS
- Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease
- (2014) Julia Kozlitina et al. NATURE GENETICS
- TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content
- (2014) H. Mahdessian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New horizons in hepatitis C antiviral therapy with direct-acting antivirals
- (2013) Alessio Aghemo et al. HEPATOLOGY
- Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?
- (2012) David van der Poorten et al. HEPATOLOGY
- Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C
- (2011) Eric Trépo et al. HEPATOLOGY
- Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection
- (2011) Francesco Marabita et al. HEPATOLOGY
- HCV and the hepatic lipid pathway as a potential treatment target
- (2011) Margaret F. Bassendine et al. JOURNAL OF HEPATOLOGY
- Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C
- (2010) Luca Valenti et al. HEPATOLOGY
- Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement
- (2009) Julian Little et al. HUMAN GENETICS
- Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C
- (2008) Ian Homer Y. Cua et al. HEPATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now